SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies ...

The Alzheimer’s Association is reminding those that winter weather conditions can be potentially dangerous and even ...

NDAQ:CMND) Clearmind Medicine Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment ...

Patrick and Carol Webb had lived all over the world. Thirty years serving in the army, while Webb was gone, Carol took care ...

For many nursing home residents, a trip to the hospital can be a jarring experience—one that leaves them confused and ...

For many nursing home residents, a trip to the hospital can be a jarring experience -; one that leaves them confused and stressed.

The company recently announced results from two Phase 3 trials of AXS-05 for agitation. ACCORD-2, hit its main goal, but ...

In one study, the company’s drug eased the agitation for Alzheimer’s patients. In a different study, there wasn’t a ...

With two earlier trials meeting their primary endpoints, Axsome claimed it has the data to support a filing for FDA approval ...

Axsome Therapeutics shows strong revenue growth with promising pipeline drugs for migraine, fibromyalgia, and narcolepsy.

On Monday, Axsome Therapeutics, Inc. (NASDAQ:AXSM) released data from ACCORD-2, ADVANCE-2, and long-term safety trials AXS-05 ...